Seer Inc
For the period ended May 28, 2025. Filed May 28, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 28, 2025 · Filed May 28, 2025
Use the contents to explore the available documents and sections.
Contents
Summary Compensation Table
The following table provides information regarding the compensation of our named executive officers during the years ended December 31, 2024 and 2023.
| Name and Principal Position | Year | Salary ($) | Stock Awards ($)(1) | Option Awards ($)(1) | Non-Equity Incentive Plan Compensation ($) | All Other Compensation ($)(2) | Total ($) |
|---|---|---|---|---|---|---|---|
| Omid Farokhzad, M.D. Chief Executive Officer | 2024 | 619,208 | 937,452 | 1,422,924 | 397,174 | 173,192 | 3,549,950 |
| 2023 | 596,459 | 1,845,180 | 2,170,350 | 423,653 | 161,689 | 5,197,331 | |
| David Horn President and Chief Financial Officer | 2024 | 525,888 | 292,117 | 389,251 | 218,264 | 2,500 | 1,428,020 |
| 2023 | 461,250 | 321,300 | 467,460 | 197,886 | 2,500 | 1,450,396 | |
| Elona Kogan (3)Former Chief Legal Officer | 2024 | 286,115 | 217,981 | 302,699 | — | 2,500 | 809,295 |
| 2023 | 416,487 | 321,300 | 467,460 | 156,870 | 2,500 | 1,364,617 |
(1)
The amount in this column represents the aggregate grant-date fair value of the award as computed as of the grant date of each restricted stock unit award and option awarded in fiscal 2024 in accordance with Financial Accounting Standard Board Accounting Standards Codification Topic 718, or ASC Topic 718, and the incremental fair value, computed as of the modification date, in accordance with ASC Topic 718, of stock options that were repriced during fiscal 2024. For additional details regarding such option repricing, see the discussion further below under “2024 Modification of Equity Grants”. The assumptions used in calculating the grant-date fair value of the awards reported in this column are set forth in the notes to our financial statements included in our Annual Report on Form 10-K filed with the SEC on March 3, 2025.
(2)
For 2024, “all other compensation” includes the following: (i) reimbursement of commuting costs of $93,569 and gross up allowance for Dr. Farokhzad of $77,123 and (ii) 401(k) plan matching contributions in the amount of $2,500 for each named executive officer. For 2023, “all other compensation” includes the following: (i) reimbursement of commuting costs of $88,532 and gross up allowance for Dr. Farokhzad of $70,657 and (ii) 401(k) plan matching contributions in the amount of $2,500 for each named executive officer.
(3)
Ms. Kogan resigned effective July 26, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.